Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis - PubMed
4 hours ago
- #Meta-Analysis
- #Chronic Kidney Disease
- #Semaglutide
- Semaglutide showed significant BMI reduction in non-diabetic obese patients with CKD or hypertension, with mean reductions ranging from 1.5% to 18.3%.
- Blood pressure control improved, with systolic blood pressure <130 mmHg increasing by 12.5% to 20.6% across studies.
- Renal function (eGFR >30 ml/min/1.73m²) improved, with increases from baseline of 4.83% to 65.8%.
- The meta-analysis included 3 studies (n=430 participants), showing semaglutide is effective and well-tolerated in this population.
- Findings support expanded use of semaglutide in non-diabetic CKD, including dialysis-dependent individuals, with no detected publication bias.